[Skip to Content]
[Skip to Content Landing]
Article
January 1978

Ticrynafen: A Novel Uricosuric Antihypertensive Natriuretic Agent

Author Affiliations

From the Hypertension Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City; and the Hypertension Research Section of the Alton Ochsner Medical Foundation, New Orleans. Drs Carvalho and Frohlich are now with the Alton Ochsner Medical Foundation, New Orleans; Dr Dunn is with the Royal Infirmary, Glasgow, Scotland; and Dr Chrysant is with the University of Oklahoma Health Sciences Center.

Arch Intern Med. 1978;138(1):53-57. doi:10.1001/archinte.1978.03630250033013
Abstract

Interest in new diuretics with less side effects has led to the synthesis of ticrynafen, an uricosuric diuretic. This agent was compared with hydrochlorothiazide in a crossover design study involving 12 hypertensive men. Both agents significantly decreased mean arterial pressure from 8% to 18% in eight of the 12 patients. In addition to reducing body weight, these diuretics induced reversible changes in BUN and carbon dioxide content (increased) and plasma concentration of potassium and chloride ions (decreased). The most important change in renal function was a 2.5-fold increase in fractional urate clearance by ticrynafen associated with reduction of serum uric acid by 62%. Thus, ticrynafen is a promising therapeutic agent in hypertension, adding a unique uricosuric effect that should improve patient compliance.

(Arch Intern Med 138:53-57, 1978)

×